{"id":14109,"date":"2018-01-30T08:44:46","date_gmt":"2018-01-30T08:44:46","guid":{"rendered":"https:\/\/celonpharma.com\/?p=14109"},"modified":"2018-02-15T08:46:01","modified_gmt":"2018-02-15T08:46:01","slug":"conclusion-of-an-agreement-on-the-industrial-development-and-manufacturing-of-the-anti-vegf-protein-a-generic-to-lucentis-for-clinical-trials","status":"publish","type":"post","link":"https:\/\/celonpharma.com\/en\/conclusion-of-an-agreement-on-the-industrial-development-and-manufacturing-of-the-anti-vegf-protein-a-generic-to-lucentis-for-clinical-trials\/","title":{"rendered":"Conclusion of an agreement on the industrial development and manufacturing of the anti-VEGF protein – a generic to Lucentis – for clinical trials"},"content":{"rendered":"

Celon Pharma S.A. concluded an agreement with Biotechpharma on industrial development of the anti-VEGF protein – a generic to Lucentis (ranibizumab) in line with GMP for the purpose of clinical trials.<\/p>\n

\n

The positive results of the work we carried out so far as well as over PLN 24 million of co-funding from the National Centre for Research and Development which we received last year for the development of this project, resulted in our decision to commence the next stage of the project assuming industrial development and manufacturing of the drug for the purpose of clinical trials. The value of the agreement concluded with Biotechpharma amounts to EUR 2-3 million, depending on the number of batches manufactured by this entity. Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A.:<\/p>\n<\/blockquote>\n

The anti-VEGF biotech drug developed by the Company will be used i.a. in age-related macular degeneration (AMD), diabetic macular oedema (DME), retinal vein occlusion [central (CRVO) or branch (BRVO)].
\nThe plans anticipates that the product will be marketed in the years 2021-2022, i.e. after basic Lucentis patents have expired. Anti-VEGF antibodies are characterised by high efficacy and the value of their global market in treatment of eye disorders exceeds ER 7 billion, whereas Lucentis has a nearly 50% market share.<\/p>\n","protected":false},"excerpt":{"rendered":"

Celon Pharma S.A. concluded an agreement with Biotechpharma on industrial development of the anti-VEGF protein – a generic to Lucentis (ranibizumab) in line with GMP for the purpose of clinical trials. The positive results of the work we carried out so far as well as over PLN 24 million of co-funding from the National CentreRead more »<\/a><\/p>\n","protected":false},"author":11,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[30],"tags":[],"class_list":["post-14109","post","type-post","status-publish","format-standard","hentry","category-general-en"],"acf":[],"yoast_head":"\nConclusion of an agreement on the industrial development and manufacturing of the anti-VEGF protein - a generic to Lucentis - for clinical trials - Celon Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/celonpharma.com\/en\/conclusion-of-an-agreement-on-the-industrial-development-and-manufacturing-of-the-anti-vegf-protein-a-generic-to-lucentis-for-clinical-trials\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Conclusion of an agreement on the industrial development and manufacturing of the anti-VEGF protein - a generic to Lucentis - for clinical trials - Celon Pharma\" \/>\n<meta property=\"og:description\" content=\"Celon Pharma S.A. concluded an agreement with Biotechpharma on industrial development of the anti-VEGF protein – a generic to Lucentis (ranibizumab) in line with GMP for the purpose of clinical trials. The positive results of the work we carried out so far as well as over PLN 24 million of co-funding from the National CentreRead more »\" \/>\n<meta property=\"og:url\" content=\"https:\/\/celonpharma.com\/en\/conclusion-of-an-agreement-on-the-industrial-development-and-manufacturing-of-the-anti-vegf-protein-a-generic-to-lucentis-for-clinical-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"Celon Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2018-01-30T08:44:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-02-15T08:46:01+00:00\" \/>\n<meta name=\"author\" content=\"S\u0142awomir Ni\u017cnik\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"S\u0142awomir Ni\u017cnik\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/conclusion-of-an-agreement-on-the-industrial-development-and-manufacturing-of-the-anti-vegf-protein-a-generic-to-lucentis-for-clinical-trials\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/conclusion-of-an-agreement-on-the-industrial-development-and-manufacturing-of-the-anti-vegf-protein-a-generic-to-lucentis-for-clinical-trials\\\/\"},\"author\":{\"name\":\"S\u0142awomir Ni\u017cnik\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/44c54386ed112173d6e8bcbeb6425338\"},\"headline\":\"Conclusion of an agreement on the industrial development and manufacturing of the anti-VEGF protein – a generic to Lucentis – for clinical trials\",\"datePublished\":\"2018-01-30T08:44:46+00:00\",\"dateModified\":\"2018-02-15T08:46:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/conclusion-of-an-agreement-on-the-industrial-development-and-manufacturing-of-the-anti-vegf-protein-a-generic-to-lucentis-for-clinical-trials\\\/\"},\"wordCount\":234,\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/conclusion-of-an-agreement-on-the-industrial-development-and-manufacturing-of-the-anti-vegf-protein-a-generic-to-lucentis-for-clinical-trials\\\/\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/conclusion-of-an-agreement-on-the-industrial-development-and-manufacturing-of-the-anti-vegf-protein-a-generic-to-lucentis-for-clinical-trials\\\/\",\"name\":\"Conclusion of an agreement on the industrial development and manufacturing of the anti-VEGF protein - a generic to Lucentis - for clinical trials - Celon Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\"},\"datePublished\":\"2018-01-30T08:44:46+00:00\",\"dateModified\":\"2018-02-15T08:46:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/44c54386ed112173d6e8bcbeb6425338\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/conclusion-of-an-agreement-on-the-industrial-development-and-manufacturing-of-the-anti-vegf-protein-a-generic-to-lucentis-for-clinical-trials\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/celonpharma.com\\\/en\\\/conclusion-of-an-agreement-on-the-industrial-development-and-manufacturing-of-the-anti-vegf-protein-a-generic-to-lucentis-for-clinical-trials\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/conclusion-of-an-agreement-on-the-industrial-development-and-manufacturing-of-the-anti-vegf-protein-a-generic-to-lucentis-for-clinical-trials\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Conclusion of an agreement on the industrial development and manufacturing of the anti-VEGF protein – a generic to Lucentis – for clinical trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\",\"name\":\"Celon Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/44c54386ed112173d6e8bcbeb6425338\",\"name\":\"S\u0142awomir Ni\u017cnik\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Conclusion of an agreement on the industrial development and manufacturing of the anti-VEGF protein - a generic to Lucentis - for clinical trials - Celon Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/celonpharma.com\/en\/conclusion-of-an-agreement-on-the-industrial-development-and-manufacturing-of-the-anti-vegf-protein-a-generic-to-lucentis-for-clinical-trials\/","og_locale":"en_US","og_type":"article","og_title":"Conclusion of an agreement on the industrial development and manufacturing of the anti-VEGF protein - a generic to Lucentis - for clinical trials - Celon Pharma","og_description":"Celon Pharma S.A. concluded an agreement with Biotechpharma on industrial development of the anti-VEGF protein – a generic to Lucentis (ranibizumab) in line with GMP for the purpose of clinical trials. The positive results of the work we carried out so far as well as over PLN 24 million of co-funding from the National CentreRead more »","og_url":"https:\/\/celonpharma.com\/en\/conclusion-of-an-agreement-on-the-industrial-development-and-manufacturing-of-the-anti-vegf-protein-a-generic-to-lucentis-for-clinical-trials\/","og_site_name":"Celon Pharma","article_published_time":"2018-01-30T08:44:46+00:00","article_modified_time":"2018-02-15T08:46:01+00:00","author":"S\u0142awomir Ni\u017cnik","twitter_card":"summary_large_image","twitter_misc":{"Written by":"S\u0142awomir Ni\u017cnik","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/celonpharma.com\/en\/conclusion-of-an-agreement-on-the-industrial-development-and-manufacturing-of-the-anti-vegf-protein-a-generic-to-lucentis-for-clinical-trials\/#article","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/conclusion-of-an-agreement-on-the-industrial-development-and-manufacturing-of-the-anti-vegf-protein-a-generic-to-lucentis-for-clinical-trials\/"},"author":{"name":"S\u0142awomir Ni\u017cnik","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/44c54386ed112173d6e8bcbeb6425338"},"headline":"Conclusion of an agreement on the industrial development and manufacturing of the anti-VEGF protein – a generic to Lucentis – for clinical trials","datePublished":"2018-01-30T08:44:46+00:00","dateModified":"2018-02-15T08:46:01+00:00","mainEntityOfPage":{"@id":"https:\/\/celonpharma.com\/en\/conclusion-of-an-agreement-on-the-industrial-development-and-manufacturing-of-the-anti-vegf-protein-a-generic-to-lucentis-for-clinical-trials\/"},"wordCount":234,"articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/celonpharma.com\/en\/conclusion-of-an-agreement-on-the-industrial-development-and-manufacturing-of-the-anti-vegf-protein-a-generic-to-lucentis-for-clinical-trials\/","url":"https:\/\/celonpharma.com\/en\/conclusion-of-an-agreement-on-the-industrial-development-and-manufacturing-of-the-anti-vegf-protein-a-generic-to-lucentis-for-clinical-trials\/","name":"Conclusion of an agreement on the industrial development and manufacturing of the anti-VEGF protein - a generic to Lucentis - for clinical trials - Celon Pharma","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/#website"},"datePublished":"2018-01-30T08:44:46+00:00","dateModified":"2018-02-15T08:46:01+00:00","author":{"@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/44c54386ed112173d6e8bcbeb6425338"},"breadcrumb":{"@id":"https:\/\/celonpharma.com\/en\/conclusion-of-an-agreement-on-the-industrial-development-and-manufacturing-of-the-anti-vegf-protein-a-generic-to-lucentis-for-clinical-trials\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/celonpharma.com\/en\/conclusion-of-an-agreement-on-the-industrial-development-and-manufacturing-of-the-anti-vegf-protein-a-generic-to-lucentis-for-clinical-trials\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/celonpharma.com\/en\/conclusion-of-an-agreement-on-the-industrial-development-and-manufacturing-of-the-anti-vegf-protein-a-generic-to-lucentis-for-clinical-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celonpharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"Conclusion of an agreement on the industrial development and manufacturing of the anti-VEGF protein – a generic to Lucentis – for clinical trials"}]},{"@type":"WebSite","@id":"https:\/\/celonpharma.com\/en\/#website","url":"https:\/\/celonpharma.com\/en\/","name":"Celon Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celonpharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/44c54386ed112173d6e8bcbeb6425338","name":"S\u0142awomir Ni\u017cnik"}]}},"_links":{"self":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/14109","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/comments?post=14109"}],"version-history":[{"count":2,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/14109\/revisions"}],"predecessor-version":[{"id":14111,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/14109\/revisions\/14111"}],"wp:attachment":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/media?parent=14109"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/categories?post=14109"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/tags?post=14109"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}